Monoclonal Antibodies for COVID-19

Lloyd, Elizabeth C; Gandhi, Tejal; Petty, Lindsay A

doi:10.1001/jama.2021.1225

Cited by 49 publications

(42 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Initially, multiple approaches were suggested to control the disease using repurposed and novel drugs [ 5 , 6 , 7 , 8 ]. Some of the repurposed drugs had demonstrated efficacy in vitro [ 9 ], yet they failed to translate into patient treatment due to high mortality [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

Long Term Immune Response Produced by the SputnikV Vaccine

Martynova

Hamza

Garanina

et al. 2021

IJMS

View full text Add to dashboard Cite

SputnikV is a vaccine against SARS-CoV-2 developed by the Gamaleya National Research Centre for Epidemiology and Microbiology. The vaccine has been shown to induce both humoral and cellular immune responses, yet the mechanisms remain largely unknown. Forty SputnikV vaccinated individuals were included in this study which aimed to demonstrate the location of immunogenic domains of the SARS-CoV-2 S protein using an overlapping peptide library. Additionally, cytokines in the serum of vaccinated and convalescent COVID-19 patients were analyzed. We have found antibodies from both vaccinated and convalescent sera bind to immunogenic regions located in multiple domains of SARS-CoV-2 S protein, including Receptor Binding Domain (RBD), N-terminal Domain (NTD), Fusion Protein (FP) and Heptad Repeats (HRs). Interestingly, many peptides were recognized by immunized and convalescent serum antibodies and correspond to conserved regions in circulating variants of SARS-CoV-2. This breadth of reactivity was still evident 90 days after the first dose of the vaccine, showing that the vaccine has induced a prolonged response. As evidenced by the activation of T cells, cellular immunity strongly suggests the high potency of the SputnikV vaccine against SARS-CoV-2 infection.

show abstract

Section: Introductionmentioning

confidence: 99%

Long Term Immune Response Produced by the SputnikV Vaccine

Martynova

Hamza

Garanina

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…The neutralizing activity of COVID-19 patients' plasma was correlated with the magnitude of antibody responses to SARS-CoV-2 S and N proteins (Post et al, 2020). To this effect, mAbs have been developed majorly against the S protein of SARS-CoV-2 owing to prevent SARS-CoV-2 infection and limit advancement to severe disease in patients with mild to moderate conditions (Lloyd et al, 2021). Disease progression is limited particularly in those who have not yet developed an endogenous antibody response (Weinreich et al, 2021).…”

Section: Monoclonal Antibodies Therapymentioning

confidence: 99%

The rapid adaptation of SARS-CoV-2–rise of the variants: transmission and resistance

Soh

Kim

et al. 2021

J Microbiol.

View full text Add to dashboard Cite

The causative factor of COVID-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuously mutating. Interestingly, identified mutations mainly occur in the spike (S) protein which interacts with the ACE2 receptor and is cleaved via serine protease TMPRSS2. Some mutated strains are becoming dominant in various parts of the globe because of increased transmissibility as well as cell entry efficacy. Remarkably, the neutralizing activity of monoclonal antibodies, convalescent sera, and vaccines against the variants has been reported to be significantly reduced. Therefore, the efficacy of various monoclonal antibodies therapy and vaccines against these variants is becoming a great global concern. We herein summarize the current status of SARS-CoV-2 with gears shifted towards the recent and most common genetic variants in relation to transmission, neutralizing activity, and vaccine efficacy.

show abstract

“…In addition to pharmacological therapy, immunization strategies targeting prevention or early treatment have proven to be crucial. Passive immunization through infusion of convalescent plasma or monoclonal antibodies has demonstrated the potential to treat the disease, especially if applied early [20][21][22][23]. Now that vaccines are available, significant attention has shifted to accelerating worldwide immunization strategies.…”

Section: Introductionmentioning

confidence: 99%

Is there a place for mesenchymal stromal cell-based therapies in the therapeutic armamentarium against COVID-19?

et al. 2021

View full text Add to dashboard Cite

The COVID-19 pandemic, caused by the rapid global spread of the novel coronavirus (SARS-CoV-2), has caused healthcare systems to collapse and led to hundreds of thousands of deaths. The clinical spectrum of COVID-19 is not only limited to local pneumonia but also represents multiple organ involvement, with potential for systemic complications. One year after the pandemic, pathophysiological knowledge has evolved, and many therapeutic advances have occurred, but mortality rates are still elevated in severe/critical COVID-19 cases. Mesenchymal stromal cells (MSCs) can exert immunomodulatory, antiviral, and pro-regenerative paracrine/endocrine actions and are therefore promising candidates for MSC-based therapies. In this review, we discuss the rationale for MSC-based therapies based on currently available preclinical and clinical evidence of safety, potential efficacy, and mechanisms of action. Finally, we present a critical analysis of the risks, limitations, challenges, and opportunities that place MSC-based products as a therapeutic strategy that may complement the current arsenal against COVID-19 and reduce the pandemic’s unmet medical needs.

show abstract

Monoclonal Antibodies for COVID-19

Cited by 49 publications

References 0 publications

Long Term Immune Response Produced by the SputnikV Vaccine

Long Term Immune Response Produced by the SputnikV Vaccine

The rapid adaptation of SARS-CoV-2–rise of the variants: transmission and resistance

Is there a place for mesenchymal stromal cell-based therapies in the therapeutic armamentarium against COVID-19?

Contact Info

Product

Resources

About